135 related articles for article (PubMed ID: 25332069)
1. Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Lalami Y; Garcia C; Flamen P; Ameye L; Paesmans M; Awada A
Head Neck; 2016 Mar; 38(3):347-54. PubMed ID: 25332069
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
Marotta V; Ramundo V; Camera L; Del Prete M; Fonti R; Esposito R; Palmieri G; Salvatore M; Vitale M; Colao A; Faggiano A
Clin Endocrinol (Oxf); 2013 May; 78(5):760-7. PubMed ID: 23009688
[TBL] [Abstract][Full Text] [Related]
3. A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck.
Adkins D; Ley J; Dehdashti F; Siegel MJ; Wildes TM; Michel L; Trinkaus K; Siegel BA
Cancer Med; 2014 Dec; 3(6):1493-501. PubMed ID: 25081631
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
[TBL] [Abstract][Full Text] [Related]
5. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
Williamson SK; Moon J; Huang CH; Guaglianone PP; LeBlanc M; Wolf GT; Urba SG
J Clin Oncol; 2010 Jul; 28(20):3330-5. PubMed ID: 20498388
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
8. Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.
Slevin F; Subesinghe M; Ramasamy S; Sen M; Scarsbrook AF; Prestwich RJ
Br J Radiol; 2015 Aug; 88(1052):20140592. PubMed ID: 26081447
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy.
Yoon DH; Cho Y; Kim SY; Nam SY; Choi SH; Roh JL; Lee SW; Song SY; Lee JH; Kim JS; Cho KJ; Kim SB
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):118-25. PubMed ID: 20675065
[TBL] [Abstract][Full Text] [Related]
11. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
12. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
13. Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?
Castaldi P; Rufini V; Bussu F; Miccichè F; Dinapoli N; Autorino R; Lago M; De Corso E; Almadori G; Galli J; Paludetti G; Giordano A; Valentini V
Radiother Oncol; 2012 Apr; 103(1):63-8. PubMed ID: 22459579
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.
Bhatt VR; Ganti AK
Future Oncol; 2014 Jan; 10(1):17-20. PubMed ID: 24328406
[No Abstract] [Full Text] [Related]
17. Prognostic significance of clinical and
Cho JK; Hyun SH; Choi JY; Choi N; Kim MJ; Lee SH; Baek KH; Jeong HS
J Surg Oncol; 2016 Dec; 114(7):888-894. PubMed ID: 27546387
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
19. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
Katsuura T; Kitajima K; Fujiwara M; Terada T; Uwa N; Noguchi K; Doi H; Tamaki Y; Yoshida R; Tsuchitani T; Fujita M; Yamakado K
Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
